The use of a marijuana strain rich in cannabidiol (CBD) in epilepsy is a complex issue and CURE’s understanding of the myriad of perspectives around this issue continue to evolve on a daily basis. As the leading private funder of epilepsy research, CURE continues to discuss new and innovative ways to navigate the regulatory issues around CBD access for research purposes.
Marijuana, and its components are classified as Schedule 1 drugs by the Drug Enforcement Agency (DEA). Because of this Schedule 1 designation, it is difficult to conduct epilepsy research using these agents, but it’s not impossible. CURE applauds those currently doing CBD research, some of whom are highlighted below, and continue to work with our many research, medical, government, and constituent partners to identify solutions that will move research even further in this important area.
No single organization tracks all research studies of medical marijuana and marijuana-based drugs and herbs and CURE hopes to be an eminent source of information on this topic.